Announcements Trials

Browse Landscape

Phase

Status

Unknown 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hemangioma 6 Hemangioma, Capillary 4 Multiple Myeloma 2 Fallopian Tube Neoplasms 2 Breast Neoplasms 2 Tuberous Sclerosis 1 Prostatic Neoplasms 1 Neuroblastoma 1 Melanoma 1 Hemangiosarcoma 1 Hemangioma, Cavernous, Central Nervous System 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Hepatocellular 1 Breast Neoplasms, Male 1

Interventions

Doxorubicin 11 Ifosfamide 10 Radiotherapy 7 pazopanib 4 Imatinib Mesylate 3 Filgrastim 3 Etoposide 3 Epirubicin 3 Chemotherapy, Adjuvant 3 Bevacizumab 3 cixutumumab 2 carotuximab 2 belinostat 2 Vincristine 2 Sunitinib 2 Sorafenib 2 Radiotherapy, Conformal 2 Paclitaxel 2 Gemcitabine 2 Dactinomycin 2 Cyclophosphamide 2 Carboplatin 2 tremelimumab 1 trebananib 1 temsirolimus 1 soblidotin 1 romidepsin 1 ribociclib 1 regorafenib 1 perifosine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Hemangiosarcoma × Propranolol × Clear all

NCT04518124 2023-11-22

Propranolol in Angiosarcoma

The Netherlands Cancer Institute

Phase 2 Completed

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡